



**Supplementary file 1: Figure S1. Mutation analysis of EZH2.** (A) the main mutation type of EZH2. (B) The primary single nucleotide variation (SNV) class type of EZH2. (C) Correlation between EZH2 expression and different mutated types. (D) The mutation spectrum of EZH2. (E) Association between EZH2 expression and copy number variation (CNV). (F) Correlation between EZH2 expression and SNV.




Supplementary file 2: Figure S2. Correlation between EZH2 expression and RNA methylation regulators (i.e., m1A, m5C, m6A). (A) m1A. (B) m5C. (C) m6A.




**Supplementary file 3: Figure S3. Heatmap of DNA methylation level of EZH2 in various cancers.**


High-expression (red); low-expression (blue).



**Supplementary file 4: Figure S4. Correlation between EZH2 expression and survival prognosis of TCGA pan-cancer patients. (A) Progression free survival. (B) Disease specific survival.**



**Supplementary file 5: Figure S5. Association analysis of EZH2 expression with clinicopathological features. (A)** The association between EZH2 expression and pathological stages. **(B)** Violin plots showing differential EZH2 expression levels in different metastasis. **(C-D)** Correlation between EZH2 expression and TNM classification (T and M stages).



**Supplementary file 6: Table S6. The correlation between EZH2 expression and several immunotherapy-related molecules. (A) Immunostimulator. (B) MHC.**